JP2024513961A5 - - Google Patents

Info

Publication number
JP2024513961A5
JP2024513961A5 JP2023562593A JP2023562593A JP2024513961A5 JP 2024513961 A5 JP2024513961 A5 JP 2024513961A5 JP 2023562593 A JP2023562593 A JP 2023562593A JP 2023562593 A JP2023562593 A JP 2023562593A JP 2024513961 A5 JP2024513961 A5 JP 2024513961A5
Authority
JP
Japan
Prior art keywords
days
once
pain
pharmaceutical composition
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023562593A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024513961A (ja
Filing date
Publication date
Priority claimed from US17/227,591 external-priority patent/US12121617B2/en
Application filed filed Critical
Priority claimed from PCT/IB2022/053276 external-priority patent/WO2022219468A1/en
Publication of JP2024513961A publication Critical patent/JP2024513961A/ja
Publication of JP2024513961A5 publication Critical patent/JP2024513961A5/ja
Pending legal-status Critical Current

Links

JP2023562593A 2021-04-12 2022-04-07 カンナビジオールの経皮送達 Pending JP2024513961A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17/227,591 US12121617B2 (en) 2019-10-14 2021-04-12 Transdermal delivery of cannabidiol
US17/227,591 2021-04-12
PCT/IB2022/053276 WO2022219468A1 (en) 2021-04-12 2022-04-07 Transdermal delivery of cannabidiol

Publications (2)

Publication Number Publication Date
JP2024513961A JP2024513961A (ja) 2024-03-27
JP2024513961A5 true JP2024513961A5 (https=) 2025-04-14

Family

ID=83640369

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023562593A Pending JP2024513961A (ja) 2021-04-12 2022-04-07 カンナビジオールの経皮送達

Country Status (7)

Country Link
EP (1) EP4322931A4 (https=)
JP (1) JP2024513961A (https=)
CN (1) CN117460503A (https=)
AU (1) AU2022257344A1 (https=)
CA (1) CA3214228A1 (https=)
MX (1) MX2023011948A (https=)
WO (1) WO2022219468A1 (https=)

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2760460C (en) * 2009-04-28 2019-04-02 Alltranz Inc. Transdermal formulations of cannabidiol comprising a penetration enhancer and methods of using the same
EP2424568A1 (en) * 2009-04-29 2012-03-07 University Of Kentucky Research Foundation Cannabinoid-containing compositions and methods for their use
PT2473475T (pt) * 2009-08-31 2017-08-02 Zynerba Pharmaceuticals Inc Utilização de profármacos de canabidiol na administração tópica e transdérmica com microagulhas
US20160022627A2 (en) * 2014-04-18 2016-01-28 Mary's Medicinals LLC Transdermal cannabinoid patch
HK1244715A1 (zh) * 2015-03-02 2018-08-17 阿福金制药有限责任公司 用大麻素的局部区域神经影响性疗法
US10272125B2 (en) * 2015-09-14 2019-04-30 Life Tech Global, Llc Transdermal delivery of cannabidiol with other active moieties including cannabinoids
JP2020530857A (ja) * 2017-08-14 2020-10-29 ジナーバ・ファーマシューティカルズ・インコーポレイテッド 経皮カンナビジオールゲルを用いた変形性関節症の治療方法
CN109498606A (zh) * 2017-09-15 2019-03-22 汉义生物科技（北京）有限公司 一种含有大麻二酚和/或次大麻二酚的组合物及其在治疗痛经中的应用
US12357604B2 (en) * 2017-09-22 2025-07-15 Inmed Pharmaceuticals Inc. Topical formulations of cannabinoids and use thereof in the treatment of pain
BR112020014253A2 (pt) * 2018-01-12 2020-12-08 Nutrae, LLC Formulações de canabinóides encapsuladas para administração oral
KR20220044558A (ko) * 2019-08-05 2022-04-08 씨에스 메디카 에이/에스 칸나비디올을 포함하는 외용 제제, 조성물의 제조 방법 및 이의 용도
EP4041209A4 (en) * 2019-10-11 2024-01-24 Pike Therapeutics, Inc. TRANSDERMAL COMPOSITIONS COMPRISING CANNABIDIOL (CBD) FOR USE IN THE TREATMENT OF EPILEPTIC DISORDERS
CA3155181A1 (en) * 2019-10-14 2021-04-22 Pike Therapeutics, Inc., 1219014 B.C. Ltd. Transdermal delivery of cannabidiol
CA3178878A1 (en) * 2020-04-20 2021-10-28 Fotios M. Plakogiannis Transdermal and/or topical pharmaceutical formulations comprising cannabidiol and/or tetrahydrocannabinol for the treatment of chronic pain
WO2022003623A1 (en) * 2020-07-01 2022-01-06 Pike Therapeutics, Inc. Transdermal pharmaceutical formulations for the treatment of multiple sclerosis
US20220047525A1 (en) * 2020-08-17 2022-02-17 Pike Therapeutics, Inc. Transdermal pharmaceutical formulations of nabilone alone and in combination with cannabinoids
CN117337174A (zh) * 2020-12-03 2024-01-02 长矛治疗股份有限公司 用于治疗癌症的包含cbd或thc的透皮药物制剂
AU2022255944A1 (en) * 2021-04-08 2023-10-12 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders

Similar Documents

Publication Publication Date Title
JP2023523155A5 (https=)
JP7670700B2 (ja) 発作性障害の治療用のカンナビジオール（ｃｂｄ）を含む経皮医薬組成物
US20050187212A1 (en) Pharmaceutical composition for topical delivery of meloxicam
US12201622B2 (en) Continuous delivery of lenalidomide and other immunomodulatory agents
JP2022551730A5 (https=)
CN103394091A (zh) 消炎镇痛外用剂
JP2022550569A5 (https=)
CN115427041A (zh) 包含羟氯喹和/或氯喹的口服递送系统
WO2005077364A1 (ja) ソリフェナシンの経皮投与製剤およびその経皮透過改善方法
JP2024514843A5 (https=)
US12016829B2 (en) Pharmaceutical composition and method for treating seizure disorders
WO1998025592A1 (fr) Preparation transdermique contenant un antagoniste des recepteurs de la serotonine
US20220040194A1 (en) Use of olanzapine for treatment of parp-inhibitor-induced nausea
JP2024513961A5 (https=)
CN117479930A (zh) 用于治疗癫痫发作病症的药物组合物和方法
CN115397402A (zh) 包含羟氯喹和/或氯喹的经皮和/或局部递送系统
JP4163859B2 (ja) 効果の高い神経弛緩剤を含有する経皮治療システム
WO2020241605A1 (ja) 外用剤
JP4986411B2 (ja) 貼付剤
WO2010098230A1 (ja) 経皮投与製剤
HK40084062A (en) Transdermal and/or topical delivery system comprising hydroxychloroquine and/or chloroquine
US20250049821A1 (en) Pharmaceutical Composition and Method for Treating Seizure Disorders
HK40060778A (en) Continuous delivery of lenalidomide and other immunomodulatory agents
WO2003068239A1 (en) Novel drugs for external use
KR20180089596A (ko) 비스테로이드계 소염진통제와 살리실산 유도체를 포함하는 경피흡수 제제